ClinicalTrials.gg
RecruitingNCT04027244LIMbUpdated Nov 4, 2020

Leg Ischaemia Management Collaboration

An observational study in Peripheral Arterial Disease, Critical Limb Ischemia and Frailty, sponsored by University of Leicester. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2020-11-04.

Primary conditionChronic Limb-Threatening IschemiaRegistry: Peripheral Arterial DiseaseReclassifiedWhy we changed it
Registry
Peripheral Arterial Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Limb-Threatening Ischemia
Why
  1. The study's listed conditions name Chronic Limb-Threatening Ischemia, a narrower term within Peripheral Arterial Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Leicester · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2022, 4 years 6 months ago, but the record still lists the study as recruiting.
  • Started May 2019; still recruiting 7 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
420
Ages
18 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom — 7 open to participants now, 9 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · United Kingdom.

Planned enrollment
2nd of 11
420 · median 250
Started
2019
with 4 others
Observational
11 of 23
6 open now
Registered
10th of 23
by date

Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2019, is one of 11 observational ones, and was the 10th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

7 of the 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 110 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom, or all of them as a file.
02

Study summary

Single-centre prospective cohort study of patients presenting with severe limb ischaemia (SLI). The primary outcome measure will be 12 month major amputation rate. A historical cohort of patients identified retrospectively will be the comparitor group used to assess the impact of a newly-established rapid-access limb salvage clinic.

Primary aim:

  • Determine the proportion of patients with SLI undergoing major lower limb amputation within 12 months of presentation.

Secondary aims:

  • Assess clinically important short-, medium- and long-term outcomes in those undergoing and not undergoing amputation
  • Prevalence and degree of frailty and cognitive impairment
  • Pevalence and degree of cardiac disease (detected by stress MRI)
  • Establish a biobank for future biomarker analysis
  • Investigate the role of frailty and cognitive assessments, cardiac MRI and biomarkers in risk-stratification of patients with SLI
Read the detailed description

Severe limb ischaemia (SLI) is the end-stage of peripheral arterial occlusive disease (PAOD) whereby the viability of the limb is threatened due to the degree of arterial disease and subsequent ischaemia in the peripheral tissues. It is defined as ischaemic rest pain (or night pain) and/or ulceration or gangrene in the affected limb(s) for a minimum of two weeks attributed to confirmed PAOD. Treatment includes open surgical and endovascular revascularisation, with or without surgical debridement of affected tissues, amputation of toes and drainage of sepsis. In some patients revascularisation is not possible or fails resulting in the person requiring a major lower limb amputation.

Over 4000 major lower limb amputations per year were undertaken in England alone between 2003 and 2013 and a diabetes-related major lower limb amputation is performed every 30 seconds world-wide. As many as 25% of people with SLI will undergo a major lower limb amputation in the first year after presentation. Amputation negatively affects quality of life due to its negative impact on mobility, independence and ability to carry out activities of daily living.

This single-centre prospective cohort study will investigate the amputation rate at one year in patients presenting with SLI and compare this to a retrospectively identified historical cohort. This study will also investigate the prevelance and degree of frailty, cognitive impairment, and cardiac disease (detected by cardiac magnetic resonance imaging (MRI)), as well as establish a biobank for future biomarker analyses. The role of frailty and cognitive assessments, cardiac MRI and biomarker analysis in risk-stratifying patients with SLI will also be investigated.

03

Conditions studied

  • Peripheral Arterial Disease
  • Critical Limb Ischemia
  • Frailty
  • Cognitive Impairment
  • Coronary Artery Disease

Keywords

  • Peripheral arterial disease
  • Limb salvage
  • Frailty
  • Cognitive dysfunction
  • Myocardial perfusion imaging
  • Biomarkers
04

In context

Chronic Limb-Threatening Ischemia Reclassified

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

This study's planned enrollment of 420 is above the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.

Browse Chronic Limb-Threatening Ischemia studies →

Lead sponsor

University of Leicester is the lead sponsor of 172 studies on the registry; 53 are open to participants now.

Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Arterial Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

As representative a sample of patients presenting to the Leicester Vascular Institute with SLI during the study period as possible. All patients presenting with SLI within the age criteria will be eligible and personal consultee consent will allow recruitment even of those patients lacking capacity to consent.

Eligibility criteria

PRIMARY COHORT

Inclusion Criteria:

  • All patients presenting to the Leicester Vascular Institute with SLI

Exclusion Criteria:

  • SLI not caused by PAOD
  • Patients undergoing intervention during their index presentation prior to recruitment
  • Patients lacking capacity to consent with no accompanying next of kin, relative, partner or friend who can act as a personal consulted
  • Patients who cannot read, write or understand English
  • Any significant disease or disorder which may either put the patient at risk because of participation in the study, or may influence the results of the study or the patient's ability to participate in the study

FRAILTY \& COGNITIVE ADDITIONAL ASSESSMENTS

Inclusion criteria:

  • Patients recruited to the primary cohort in whom a decision has been made to undergo an intervention for SLI
  • Patients aged ≥65 years

Exclusion criteria:

  • Nil additional

CARDIAC MRI ADDITIONAL ASSESSMENTS

Inclusion criteria:

  • Patients recruited to the primary cohort in whom a decision has been made to undergo an intervention

Exclusion criteria:

  • Absolute to cardiac MRI (Pregnancy, Non-MR safe permanent pacemaker, implanted cardiac defibrillator, intra-auricular implant or intra-cranial clips, severe claustrophobia, unstable angina)
  • Contraindication to gadolinium contrast agent (Known adverse reaction, chronic renal failure ( \<30mL/min/1.73m\^2))
  • Patients lacking capacity to consent for cardiac MRI

BIOMARKERS ADDITIONAL ASSESSMENTS

  • Patients recruited to the primary cohort in whom a decision has been made to undergo an intervention

Exclusion criteria:

  • Nil additional
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
420 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Primary cohort

    Any patient presenting to the Leicester Vascular Institute with SLI during the 2 year recruitment period (minimum 420 patients).

  • Frailty & cognitive additional assessments

    Any patient recruited to the primary cohort aged ≥65 years and undergoing an intervention for SLI (minimum 150 patients, target 210 patients).

  • Cardiac MRI additional assessments

    Any patient recruited to the primary cohort, with capacity to consent and undergoing an intervention for SLI (minimum 100 patients).

  • Biomarkers additional assessments

    Any patient recruited to the primary cohort and undergoing an intervention for SLI (no target recruitment set).

  • Historical cohort

    Retrospectively identified cohort of patients presenting to the study site with SLI between 2013 -15 (target 420).

07

What researchers measure

Primary outcomes

  1. 12 month amputation rate

    Proportion of patients undergoing major lower limb amputation

    Time frame: 12 months post recruitment

Secondary outcomes

  1. Amputation free survival

    Composite outcome measure of death or amputation

    Time frame: ≥12 months post recruitment

  2. All-cause mortality

    Death from any cause

    Time frame: ≥12 months

  3. Quality of life

    Quality of life as measured by the Vascular Quality of Life questionnaire (VascuQoL) * 25 item questionnaire, score 1-7 for each item, higher score = better quality of life * Domains: activities (8 items), symptoms (4 items), pain (4 items), social (2 items) and emotional (7 items); each scored 1-7 (total of domain item scores/number of items) * Overall score 1-7 (total item score/25)

    Time frame: 12 and 24 months post recruitment

  4. Disability

    Level of disability as measured by the Barthel Index - Score 0-20; higher score = greater degree of functional independence/lower level of disability

    Time frame: 12 and 24 months post recruitment

  5. Clinical Frailty Scale

    Prevalence and degree of frailty as measured by the Clinical Frailty Scale (CFS) * Score 1-9, higher score = greater degree of frailty * Results will also be reported dichotomised to frail (score ≥5) and non-frail (score ≤4)

    Time frame: Baseline, 12 and 24 months

  6. Anxiety & Depression

    Prevalence and degree of anxiety and depression as measured by the Hospital Anxiety and Depression Scale (HADS) * 14 item questionnaire; score 0-3 for each item, higher score = more severe anxiety/depression * Domains: Depression (7 items), Anxiety (7 items); each scored 0-21; 0-7 = normal, 8-10 = bordeline, 11-21 = abnormal (case).

    Time frame: Baseline, 12 and 24 months

Other outcomes

  1. Cognitive impairment (Frailty & Cognitive additional assessments only)

    Prevalence of cognitive impairment as detected by the Montreal Cognitive Assessment (MoCA) * Score 0-30; highger score = greater level of cognitive function * Results will also be reported dichotomised to normal (score ≥24) and cognitive impairment (score ≤23)

    Time frame: Baseline, 3 and 12 months

  2. Post-operative delirium (Frailty & Cognitive additional assessments only)

    Incidence of post-operative delirium as detected by the Single Question in Delirium (SQiD) +/- 4 A's Test for delirium (4AT)

    Time frame: 24 and 72 hours post intervention

  3. Prevalence of coronary artery disease (Cardiac MR additional assessments only)

    Prevalence of coronary artery disease as detected by stress cardiac MRI

    Time frame: Baseline

  4. Incidence of peri-operative myocardial infarction (Cardiac MR additional assessments only)

    Incidence of peri-operative myocardial infarction as detected by cardiac MRI

    Time frame: 2-4 months post intervention

  5. Edmonton Frail Scale (Frailty & Cognitive additional assessments only)

    Prevalence and degree of frailty as measured by the Edmonton Frail Scale (EFS) * Score 0-17, 0-5 = not frail, 6-7 = vulnerable, 8-9 = mild frailty, 10-11 = moderate frailty, 12-17 = severe frailty * Results will also be reported dichotomised to frail (score ≥8) and non-frail (score ≤7)

    Time frame: Baseline, 3 and 12 months

08

Study locations

1 of 1 sites recruiting
  • Glenfield Hospital Leicester
    Leicester, Leicestershire LE3 9QP, United Kingdom
    Recruiting
    • Tanya J Payne · Contacttjp28@le.ac.uk · +44 (0)116 358 3867
    • Rob D Sayers, MD · Principal investigator
    • Matt J Bown, MD · Sub investigator
    • Thompson G Robinson, MD · Sub investigator
    • Gerry P McCann, MD · Sub investigator
    • Victoria J Haunton, MD · Sub investigator
    • Sally J Singh, PhD · Sub investigator
    • Robert SM Davies, MD · Principal investigator
    • Tanya J Payne, BSc · Sub investigator
    • Laura J Gray, PhD · Sub investigator
    • Harjeet S Rayt, MD · Sub investigator
    • Gregory S McMahon, MD · Sub investigator
09

References and documents

Publications

  • Houghton JSM, Nduwayo S, Nickinson ATO, Payne TJ, Sterland S, Nath M, Gray LJ, McMahon GS, Rayt HS, Singh SJ, Robinson TG, Conroy SP, Haunton VJ, McCann GP, Bown MJ, Davies RSM, Sayers RD. Leg ischaemia management collaboration (LIMb): study protocol for a prospective cohort study at a single UK centre. BMJ Open. 2019 Sep 3;9(9):e031257. doi: 10.1136/bmjopen-2019-031257. PubMed 31481569 ↗

Individual participant data

Plan to share: Undecided — Anonymised dataset will be available on request to the Chief Investigator (Prof Rob Sayers). The study protocol will be published in an open-access journal prior to completion of recruitment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for May 2022, 35 months after the start.

Of 47 non-industry observational studies under Chronic Limb-Threatening Ischemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's planned 35 months is close to that.

Counting every sponsor, half of 53 studies reached it within 34 months; a quarter within 22 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2019
First posted
Jul 19, 2019
StartActual
May 10, 2019
Primary completionEst.
May 9, 2022
CompletionEst.
May 9, 2031
Last update
Nov 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04027244
Collaborators
University Hospitals, Leicester, National Institute for Health Research, United Kingdom, The George Davies Charitable Trust
Responsible party
Sponsor
First posted
Jul 19, 2019
Start date
May 10, 2019
Primary completion
May 9, 2022 (estimated)
Completion
May 9, 2031 (estimated)
Last update
Nov 4, 2020

Study contacts

Rob D Sayers, MD
Contact
rs152@le.ac.uk
+44 (0)116 252 3141
Tanya J Payne, BSc
Contact
tjp28@le.ac.uk
+44 (0)116 258 3867
Rob D Sayers, MD
study chair · University of Leicester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion